Genesys Capital invests in and builds companies in the high-growth sectors of life sciences. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies.
Employees: 1-10
Portfolio 22
| Date | Name | Website | Total Raised | Location |
| 01.11.2024 | Feldan | feldan.com | $16.5M | Canada, On... |
| 27.10.2023 | Cryostasis... | cryostasis.ca | - | Canada |
| 27.10.2023 | giiant pha... | giiant.com | $11M | Canada, Mo... |
| 02.06.2022 | Fusion Pha... | fusionpharma.com | $195.91M | Canada, On... |
| 30.01.2022 | Questat In... | questat.ca | - | - |
| 30.01.2022 | Veralox Th... | veralox.com | $22M | United Sta... |
| - | Inversago ... | inversago.com | $137M | - |
| - | Ionalytics... | thermo.com | - | United Sta... |
| - | Debiopharm | debiopharm.com | - | Switzerlan... |
| - | Adapsyn Bi... | adapsyn.com | - | - |
Show more
Persons 6
| Date | First Name | Last Name | Title | Location | |||
| - | Paras | Sharma | Senior Ass... | - | - | - | |
| - | Kelly | Holman | Co-founder... | - | - | - | |
| - | Damian | Lamb | Co-founder... | - | - | - | |
| - | Jamie | Stiff | Managing D... | - | - | - | |
| - | Christine | Thoburn | Office Man... | - | - | - | |
| - | Sarah | Farr | Senior Ass... | - | - | - |
Mentions in press and media 11
| Date | Title | Description |
| 08.07.2026 | Genesys University Seed Fund Holds First Close With Over $30 Million In Commitments | The University of Toronto, McMaster University, Venture Ontario, and Genesys Capital announced the creation of a new early-stage life sciences venture capital fund. The Genesys University Seed Fund has held a first close representing over $... |
| 13.01.2026 | Enspire DBS Therapy Secured $10.3 Million Series B1 To Advance DBS-Enabled Stroke Rehabilitation Trial | Enspire DBS Therapy, a Cleveland-based clinical-stage medical device company developing an implantable neuromodulation approach for post-stroke recovery, has raised $10.3 million in a Series B1 financing to support pivotal clinical developm... |
| 13.01.2026 | Enspire DBS Therapy Raises $10.3M in Series B1 Funding | Enspire DBS Therapy, Inc., a Cleveland, OH-based clinical-stage company developing an implantable neuromodulation therapy for post-stroke recovery, raised $10.3M in a Series B1 funding. The round was led by new investor Genesys Capital, wit... |
| 13.06.2025 | The Rise of Canadian Life Sciences: A New Era of Innovation and Investment | In the heart of Canada, a revolution is brewing. The life sciences sector is experiencing a surge, fueled by innovative companies and strategic investments. Two recent announcements highlight this trend: Genesys Capital's closing of its lar... |
| 11.06.2025 | Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP | TORONTO & MONTREAL–(BUSINESS WIRE)–June 11, 2025– Genesys Capital (“Genesys”) is pleased to announce the upcoming closing of Genesys Ventures IV LP (“Fund IV” or the “fund”) to continue its successful track record of building Canadian l... |
| 06.03.2020 | Aortyx cierra una ronda de €650.000 liderada por Genesis Ventures | 06/03/2020 Nota de prensa AORTYX CIERRA UNA RONDA DE €650.000 LIDERADA POR GENESIS VENTURES. Aortyx, ‘spin-off’ del IQS especializada en la creación de dispositivos endovasculares para las disecciones aórticas, ha ampliado capital en 650... |
| 24.08.2016 | Genesys Capital closes $90 million of its $125 million target for third fund | Toronto-based Genesys Capital, which is focused on investing in seed healthcare startups, announced that it’s closed $90 million of its $125 million target for its third fund, according to PE Hub. Managing director Damian Lamb said that it ... |
| 17.12.2012 | Naurex Raises $38M in Series B Financing | Naurex Inc., an Evanston, Illinois-based clinical-stage company focused on psychiatry and neurology, has raised $38m in Series B financing. The round was led by new investor Baxter Ventures, with participation from new investor Savitr Capit... |
| - | Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments | HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing... |
| - | Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics | HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Se... |
Show more